New staggered drug combo aims to outsmart lung cancer
NCT ID NCT04163432
First seen Jun 27, 2026 · Last updated Jul 23, 2026 · Updated 2 times
Summary
This phase II study tests two staggered schedules of the immunotherapy drug durvalumab combined with standard chemotherapy (pemetrexed and carboplatin) in 43 adults with advanced non-squamous non-small cell lung cancer. The goal is to see if changing the timing of the drugs improves tumor control and keeps side effects manageable. Participants have not received prior chemo-immunotherapy and must have measurable disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- durvalumab (Imfinzi) plus pemetrexed (Alimta) and carboplatin
- What this could lead to
- If successful, this could point toward a more effective way to schedule immunotherapy and chemotherapy for advanced lung cancer, potentially improving tumor shrinkage and delaying progression.
- What could go wrong
- This is a small, early-phase trial with only 43 participants, so results may not apply to all patients. The staggered dosing could also increase side effects without improving outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Huntsman Cancer Institute at University of Utah
Salt Lake City, Utah, 84112, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a triple-drug cocktail re-sensitize lung cancer to treatment?
- Could a lung cancer drug designed for one mutation work for another?
- Could chemo plus immunotherapy double the punch against tough lung cancers?
- Should all advanced lung cancer patients get a brain scan? new trial aims to find out
- New hope for tough lung cancer? trial tests targeted drug against chemo
- New combo therapy for lung cancer under Real-World watch